The NK cancer drug provider has filed to go public in an offering which would enable GC and its GC Labcell subsidiary to exit.

Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.

The oncology drug developer, backed by Bristol Myers Squibb, secured close to $144m in its IPO. This is an exit from a space that has seen much corporate support over the past decade.

The Tencent-backed video game holding group has applied to float in a Korean initial public offering which could value it at about $18bn.

The cancer therapeutics developer has filed to float on the Nasdaq Global Market, with Taiho Ventures set to achieve an exit.

The Microsoft, Caterpillar, Schlumberger and Delta-backed industrial robotics provider is merging with publicly-listed Rotor Acquisition Corp.

The Bristol Myers Squibb-backed oncology drug developer ultimately raised nearly $144m in its initial public offering.

Vision Fund and Advance Publications scored exits but the real estate portal operator ended up significantly downsizing its initial public offering.

The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.

The Alibaba, SoftBank and Xiaomi-backed mobile charger producer has floated below its range in a $150m initial public offering.